Published in Nature on February 02, 2011
The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 7.32
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell (2011) 3.88
Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell (2014) 3.05
Prevention and early detection of prostate cancer. Lancet Oncol (2014) 2.94
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene (2013) 2.64
Origins of metastatic traits. Cancer Cell (2013) 2.49
COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis. Nature (2012) 2.11
Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet (2013) 2.11
JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A (2012) 1.88
IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res (2011) 1.87
Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell (2012) 1.75
Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell (2011) 1.74
Beyond TGFβ: roles of other TGFβ superfamily members in cancer. Nat Rev Cancer (2013) 1.67
Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res (2013) 1.66
STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat Commun (2015) 1.63
Vitamin D and cancer: a review of molecular mechanisms. Biochem J (2012) 1.51
Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci U S A (2015) 1.51
Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene (2011) 1.50
Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature (2017) 1.50
CAPER is vital for energy and redox homeostasis by integrating glucose-induced mitochondrial functions via ERR-α-Gabpa and stress-induced adaptive responses via NF-κB-cMYC. PLoS Genet (2015) 1.49
Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature (2017) 1.41
Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer. Clin Cancer Res (2015) 1.39
Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci U S A (2014) 1.38
A molecular signature predictive of indolent prostate cancer. Sci Transl Med (2013) 1.32
Mechanisms of cancer cell metastasis to the bone: a multistep process. Future Oncol (2011) 1.27
Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer (2013) 1.25
Functional screening for miRNAs targeting Smad4 identified miR-199a as a negative regulator of TGF-β signalling pathway. Nucleic Acids Res (2012) 1.24
β-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma. PLoS Genet (2013) 1.24
A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer Prostatic Dis (2013) 1.23
Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. Br J Cancer (2013) 1.23
Suppression of survival signalling pathways by the phosphatase PHLPP. FEBS J (2012) 1.23
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science (2017) 1.22
Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov (2012) 1.22
The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol Oncol (2012) 1.21
High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol (2014) 1.18
Notch and TGFβ form a reciprocal positive regulatory loop that suppresses murine prostate basal stem/progenitor cell activity. Cell Stem Cell (2012) 1.16
Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res (2011) 1.15
microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer. Br J Cancer (2013) 1.14
Turning off AKT: PHLPP as a drug target. Annu Rev Pharmacol Toxicol (2014) 1.12
NF-κB gene signature predicts prostate cancer progression. Cancer Res (2014) 1.09
Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev (2013) 1.08
miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration. Cell Cycle (2013) 1.03
Alterations in osteopontin modify muscle size in females in both humans and mice. Med Sci Sports Exerc (2013) 1.03
Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer. Prostate Cancer Prostatic Dis (2015) 1.02
Transcriptome profiling of archived sectioned formalin-fixed paraffin-embedded (AS-FFPE) tissue for disease classification. PLoS One (2014) 1.01
Molecular pathways and targets in prostate cancer. Oncotarget (2014) 1.00
The metabolic co-regulator PGC1α suppresses prostate cancer metastasis. Nat Cell Biol (2016) 1.00
Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. J Clin Invest (2013) 0.99
Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. Cancer Discov (2015) 0.98
Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer. FEBS Lett (2012) 0.98
Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br J Cancer (2014) 0.98
Prostate cancer - a biomarker perspective. Front Endocrinol (Lausanne) (2012) 0.97
Does the microenvironment influence the cell types of origin for prostate cancer? Genes Dev (2013) 0.97
The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models. Front Oncol (2014) 0.96
Prognostic determinants in prostate cancer. Cancer J (2011) 0.95
Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy. Clin Exp Metastasis (2015) 0.94
The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer Metastasis Rev (2014) 0.94
The AR dependent cell cycle: mechanisms and cancer relevance. Mol Cell Endocrinol (2011) 0.93
RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov (2014) 0.93
Biomarker identification for prostate cancer and lymph node metastasis from microarray data and protein interaction network using gene prioritization method. ScientificWorldJournal (2012) 0.93
Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev (2014) 0.93
Current mouse and cell models in prostate cancer research. Endocr Relat Cancer (2013) 0.92
HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proc Natl Acad Sci U S A (2011) 0.92
Novel tumor suppressive function of Smad4 in serum starvation-induced cell death through PAK1-PUMA pathway. Cell Death Dis (2011) 0.92
Attenuation of TGF-β signaling suppresses premature senescence in a p21-dependent manner and promotes oncogenic Ras-mediated metastatic transformation in human mammary epithelial cells. Mol Biol Cell (2012) 0.91
Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. Neoplasia (2012) 0.91
Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis. Oncogene (2013) 0.91
Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality. Proteome Sci (2014) 0.91
Structural basis for the cooperative DNA recognition by Smad4 MH1 dimers. Nucleic Acids Res (2011) 0.91
Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells. Br J Cancer (2014) 0.90
Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer. PLoS One (2014) 0.90
Active surveillance for prostate cancer: an underutilized opportunity for reducing harm. J Natl Cancer Inst Monogr (2012) 0.90
Reduced expression of SMAD4 in gliomas correlates with progression and survival of patients. J Exp Clin Cancer Res (2011) 0.89
Novel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures. Cancer Res (2012) 0.89
Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype. Lab Invest (2014) 0.89
SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma. Oncogene (2014) 0.89
Critical role of a survivin/TGF-β/mTORC1 axis in IGF-I-mediated growth of prostate epithelial cells. PLoS One (2013) 0.89
Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget (2014) 0.89
Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint. Cancer Res (2013) 0.89
Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer. J Clin Invest (2014) 0.88
The TNF family member APRIL promotes colorectal tumorigenesis. Cell Death Differ (2012) 0.88
Bone morphogenetic protein- and mating-dependent secretory cell growth and migration in the Drosophila accessory gland. Proc Natl Acad Sci U S A (2012) 0.87
SMAD4 is a potential prognostic marker in human breast carcinomas. Tumour Biol (2013) 0.86
Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer. Carcinogenesis (2014) 0.86
Evaluation of protein biomarkers of prostate cancer aggressiveness. BMC Cancer (2014) 0.86
Association of prostate cancer risk alleles with unfavourable pathological characteristics in potential candidates for active surveillance. BJU Int (2011) 0.86
The heterotrimeric laminin coiled-coil domain exerts anti-adhesive effects and induces a pro-invasive phenotype. PLoS One (2012) 0.85
Performance of an adipokine pathway-based multilocus genetic risk score for prostate cancer risk prediction. PLoS One (2012) 0.85
Genetic variations in the transforming growth factor beta pathway as predictors of bladder cancer risk. PLoS One (2012) 0.85
Betulinic acid selectively increases protein degradation and enhances prostate cancer-specific apoptosis: possible role for inhibition of deubiquitinase activity. PLoS One (2013) 0.85
Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers. Prostate Cancer (2012) 0.84
Management of low (favourable)-risk prostate cancer. BJU Int (2011) 0.84
Drug Discov Today Dis Models (2011) 0.84
The role of the orphan nuclear receptor COUP-TFII in tumorigenesis. Acta Pharmacol Sin (2014) 0.84
Cooperativity of E-cadherin and Smad4 loss to promote diffuse-type gastric adenocarcinoma and metastasis. Mol Cancer Res (2014) 0.83
The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer. Neoplasia (2012) 0.83
Liver x receptors protect from development of prostatic intra-epithelial neoplasia in mice. PLoS Genet (2013) 0.82
Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer. PLoS One (2015) 0.82
Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways. Neoplasia (2014) 0.82
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med (1989) 13.83
Smad transcription factors. Genes Dev (2005) 13.43
Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 12.25
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Natural history of early, localized prostate cancer. JAMA (2004) 7.44
Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol (2004) 6.99
Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev (2000) 5.71
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev (2006) 5.53
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00
Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest (2004) 4.59
Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev (2001) 4.47
Design of Physicians' Health Study II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol (2000) 4.21
FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis. Cell Stem Cell (2009) 3.37
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Bioinformatics (2008) 2.34
Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res (2004) 2.32
Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res (2005) 2.19
Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Hum Pathol (2004) 1.82
Clinical practice. Localized prostate cancer. N Engl J Med (2007) 1.72
Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol (2010) 1.61
A human prostatic epithelial model of hormonal carcinogenesis. Cancer Res (2001) 1.40
TGFbeta and BMP-2 activation of the OPN promoter: roles of smad- and hox-binding elements. Exp Cell Res (2001) 1.25
Hoxa-9 represses transforming growth factor-beta-induced osteopontin gene transcription. J Biol Chem (2001) 1.18
Modeling prostate cancer: a perspective on transgenic mouse models. Cancer Metastasis Rev (2010) 1.15
Targeted therapy of cancer: new roles for pathologists--prostate cancer. Mod Pathol (2008) 1.13
Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. Carcinogenesis (2006) 1.09
Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. Prostate (2008) 1.08
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature (2005) 31.60
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Towards a proteome-scale map of the human protein-protein interaction network. Nature (2005) 24.76
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
International network of cancer genome projects. Nature (2010) 20.35
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
A map of the interactome network of the metazoan C. elegans. Science (2004) 15.60
Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet (2007) 15.46
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med (2002) 14.01
An integrated software system for analyzing ChIP-chip and ChIP-seq data. Nat Biotechnol (2008) 13.96
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
A mitochondrial protein compendium elucidates complex I disease biology. Cell (2008) 13.51
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med (2008) 12.41
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA (2004) 11.69
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
High-quality binary protein interaction map of the yeast interactome network. Science (2008) 10.65
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A (2004) 10.47
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 10.05
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell (2003) 9.81
Extensive and divergent circadian gene expression in liver and heart. Nature (2002) 9.64
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med (2003) 9.24
Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature (2006) 9.20
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94
Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med (2004) 8.63
A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell (2006) 8.61
Highly recurrent TERT promoter mutations in human melanoma. Science (2013) 8.40
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature (2008) 8.38
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev (2003) 8.27
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2006) 8.26
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
GoSurfer: a graphical interactive tool for comparative analysis of large gene sets in Gene Ontology space. Appl Bioinformatics (2004) 7.84
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol (2002) 7.44
A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care (2003) 7.40
Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell (2009) 7.39
Pancreatic cancer biology and genetics. Nat Rev Cancer (2002) 7.36